GlassScriptPhysician profile
Tanner Cook
NPI 1629545579
$1,574.97
in general payments reported to CMS, 2019-2025
29 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $558 · 2023: $440 · 2024: $162 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Entertainment: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.91 |
| Entertainment | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.26 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.27 | 2022-2023 | |
| Glaxosmithkline, LLC. | $151.98 | 2022-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $102.21 | 2022-2025 | Pifeltro, Capvaxive |
| Novo Nordisk INC | $95.56 | 2022-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $74.52 | 2022-2023 | |
| Viiv Healthcare Company | $63.92 | 2025 | Cabenuva |
| Abbott Laboratories | $63.59 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $55.26 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Insulet Corporation | $55.15 | 2023 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $50.12 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $43.43 | 2021 | |
| Gilead Sciences, INC. | $42.79 | 2025 | |
| Alkermes, INC. | $40.41 | 2021 | |
| Smith+Nephew, INC. | $26.75 | 2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.65 | 2023 | Spinraza |
| Lucid Diagnostics INC. | $24.20 | 2022 | |
| Amgen INC. | $22.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.29 | 2023 | Gvoke Hypopen |
| Napo Pharmaceuticals INC | $18.90 | 2025 | Mytesi |
| Astellas Pharma US INC | $18.60 | 2023 | Myrbetriq |
| Organon LLC | $17.77 | 2025 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $17.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.80 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.27 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.96 | 2023 | |
| Optos, INC. | $14.00 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Exact Sciences Corporation | $13.69 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.